- Home
- KULR vs CCCC Comparison
KULR vs CCCC Comparison
Compare KULR & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KULR
- CCCC
- Stock Information
- Founded
- KULR 2013
- CCCC 2015
- Country
- KULR United States
- CCCC United States
- Employees
- KULR N/A
- CCCC N/A
- Industry
- KULR Electrical Products
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- KULR Technology
- CCCC Health Care
- Exchange
- KULR Nasdaq
- CCCC Nasdaq
- Market Cap
- KULR 163.0M
- CCCC 160.1M
- IPO Year
- KULR N/A
- CCCC 2020
- Fundamental
- Price
- KULR $3.12
- CCCC $2.30
- Analyst Decision
- KULR Strong Buy
- CCCC Strong Buy
- Analyst Count
- KULR 2
- CCCC 4
- Target Price
- KULR $40.00
- CCCC $8.50
- AVG Volume (30 Days)
- KULR 2.2M
- CCCC 2.1M
- Earning Date
- KULR 11-13-2025
- CCCC 11-06-2025
- Dividend Yield
- KULR N/A
- CCCC N/A
- EPS Growth
- KULR N/A
- CCCC N/A
- EPS
- KULR N/A
- CCCC N/A
- Revenue
- KULR $12,977,975.00
- CCCC $30,108,000.00
- Revenue This Year
- KULR $27.50
- CCCC N/A
- Revenue Next Year
- KULR $164.50
- CCCC N/A
- P/E Ratio
- KULR N/A
- CCCC N/A
- Revenue Growth
- KULR 35.81
- CCCC N/A
- 52 Week Low
- KULR $2.44
- CCCC $1.09
- 52 Week High
- KULR $43.92
- CCCC $6.25
- Technical
- Relative Strength Index (RSI)
- KULR 30.70
- CCCC 45.73
- Support Level
- KULR $3.88
- CCCC $2.24
- Resistance Level
- KULR $4.35
- CCCC $2.46
- Average True Range (ATR)
- KULR 0.23
- CCCC 0.20
- MACD
- KULR -0.10
- CCCC -0.01
- Stochastic Oscillator
- KULR 17.48
- CCCC 18.55
About KULR KULR Technology Group Inc.
KULR Technology Group Inc develops and commercializes high-performance thermal management technologies for electronics, batteries, and other components. The company is focused on targeting the following applications: electric vehicles and autonomous driving systems, artificial intelligence and Cloud computing, energy storage, 5G communication technologies, and other consumer and industrial devices.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.